Malignancy as an etiological factor involved in priapism pathogenesis is rare. Malignant priapism (MP) can arise as a result of penile tumor invasion, either from primary penile tumors or from metastatic penile tumors, or due to hematological malignancies. Non-urological penile metastases are associated with significant worse prognosis compared to urological penile metastases, the appearance of priapism in such cases affecting even more the prognosis and the survival of these patients. Patients diagnosed with hematological malignancies and priapism present significant higher survival rates compared to those who develop MP in the context of a non-hematological malignancy, this being related to the fact that hematological malignancies are more sensitive to chemo- and radiotherapy. Most malignant priapism cases are ischemic; therefore the management should be based on the initial steps of the IP therapeutic protocol. Considering the trigger factor that has led to the priapic event specific oncologic treatment can be added as well.

中文翻译：

---

恶性阴茎异常勃起——我们对它了解多少？

恶性肿瘤作为与阴茎异常勃起发病机制有关的病因因素是罕见的。恶性阴茎异常勃起 (MP) 可能是阴茎肿瘤侵袭的结果，可以是原发性阴茎肿瘤或转移性阴茎肿瘤，也可以是血液系统恶性肿瘤。与泌尿系统阴茎转移瘤相比，非泌尿系统阴茎转移瘤预后更差，在这种情况下阴茎异常勃起的出现对这些患者的预后和生存影响更大。与在非血液系统恶性肿瘤背景下发生 MP 的患者相比，诊断为血液系统恶性肿瘤和阴茎异常勃起的患者的存活率显着更高，这与血液系统恶性肿瘤对化疗和放疗更敏感的事实有关。大多数恶性阴茎异常勃起是缺血性的；因此，管理应基于 IP 治疗方案的初始步骤。考虑到导致阴茎异常勃起事件的触发因素，也可以添加特定的肿瘤治疗。